MCID: CHR286
MIFTS: 49

Chronic Neutrophilic Leukemia

Categories: Rare diseases, Cancer diseases, Blood diseases, Immune diseases

Aliases & Classifications for Chronic Neutrophilic Leukemia

MalaCards integrated aliases for Chronic Neutrophilic Leukemia:

Name: Chronic Neutrophilic Leukemia 12 49 55 69
Leukemia Neutrophilic Chronic 51
Cnl 49

Characteristics:

Orphanet epidemiological data:

55
chronic neutrophilic leukemia
Age of onset: Adult;

Classifications:



External Ids:

Disease Ontology 12 DOID:0080187
NCIt 46 C3179
Orphanet 55 ORPHA86829
MESH via Orphanet 42 D015467
UMLS via Orphanet 70 C0023481
ICD10 via Orphanet 33 D47.1
UMLS 69 C0023481

Summaries for Chronic Neutrophilic Leukemia

Disease Ontology : 12 A chronic leukemia characterized by neutrophilic leukocytosis with no detectable Philadelphia chromosome or BCR/ABL fusion gene.

MalaCards based summary : Chronic Neutrophilic Leukemia, also known as leukemia neutrophilic chronic, is related to atypical chronic myeloid leukemia and polycythemia vera. An important gene associated with Chronic Neutrophilic Leukemia is CSF3R (Colony Stimulating Factor 3 Receptor), and among its related pathways/superpathways are Pathways in cancer and Jak-STAT signaling pathway (KEGG). The drugs Mycophenolic acid and Mycophenolate mofetil have been mentioned in the context of this disorder. Affiliated tissues include neutrophil, bone and bone marrow, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 72 Chronic neutrophilic leukemia (CNL) is a rare myeloproliferative neoplasm that features a persistent... more...

Related Diseases for Chronic Neutrophilic Leukemia

Diseases related to Chronic Neutrophilic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Related Disease Score Top Affiliating Genes
1 atypical chronic myeloid leukemia 30.2 ASXL1 CSF3R SETBP1
2 polycythemia vera 29.6 ASXL1 CALR IFNA1
3 neutropenia 29.0 CSF3 CSF3R IFNA1 IFNA2
4 myelodysplastic syndrome 29.0 ASXL1 CD34 CSF3 CSF3R KMT2A SETBP1
5 leukemia, chronic myeloid 28.6 CD34 CSF3 IFNA1 IFNA2 SETBP1
6 myelofibrosis 27.5 ASXL1 CALR CD34 CSF3 IFNA1 IFNA2
7 myeloproliferative neoplasm 11.1
8 leukemia 10.7
9 sm-ahnmd 10.3 ASXL1 SRSF2
10 myelodysplastic myeloproliferative cancer 10.2 ASXL1 CSF3R SETBP1
11 refractory anemia with excess blasts 10.1 ASXL1 CSF3 SETBP1
12 splenomegaly 10.1 IFNA2 SETBP1
13 trigonitis 10.1 CD34 CSF3
14 chronic myelomonocytic leukemia 10.0
15 pdgfrb-associated chronic eosinophilic leukemia 10.0
16 orbital granuloma 10.0 CD34 CSF3
17 lymphomatoid granulomatosis 10.0 IFNA1 IFNA2
18 squamous papillomatosis 10.0 IFNA1 IFNA2
19 polycythemia 10.0
20 hemangioma of liver 10.0 CD34 IFNA2
21 myeloma, multiple 10.0
22 cryoglobulinemia, familial mixed 9.9 IFNA1 IFNA2
23 engraftment syndrome 9.9 CSF3 IFNA1
24 myeloid leukemia 9.9
25 severe congenital neutropenia 9.8
26 bone marrow cancer 9.8 CSF3 CSF3R IFNA1
27 exophthalmos 9.7 ASXL1 CD34
28 discoid lupus erythematosus 9.7 IFNA1 IFNA2
29 stomatitis 9.7 CSF3 IFNA1 IFNA2
30 aplastic anemia 9.7 ASXL1 CD34 CSF3 CSF3R
31 leukemia, chronic lymphocytic 2 9.7
32 leukemia, chronic lymphocytic 9.7
33 neutrophilia, hereditary 9.7
34 polykaryocytosis inducer 9.7
35 hemophilia a 9.7
36 mycobacterium tuberculosis 1 9.7
37 cerebral hemorrhage 9.7
38 nephrotic syndrome 9.7
39 cerebritis 9.7
40 plasma cell neoplasm 9.7
41 amyloidosis 9.7
42 miliary tuberculosis 9.7
43 hemophilia 9.7
44 acquired hemophilia 9.7
45 acquired hemophilia a 9.7
46 leukemia, b-cell, chronic 9.7
47 essential thrombocythemia 9.6 ASXL1 CALR IFNA1 IFNA2
48 acquired immunodeficiency syndrome 9.6 CD34 IFNA1 IFNA2
49 lymphoma, non-hodgkin, familial 9.6 BIRC3 CD34 CSF3 XIAP
50 leukemia, acute lymphoblastic 9.6 AFF1 CD34 CSF3 KMT2A

Graphical network of the top 20 diseases related to Chronic Neutrophilic Leukemia:



Diseases related to Chronic Neutrophilic Leukemia

Symptoms & Phenotypes for Chronic Neutrophilic Leukemia

GenomeRNAi Phenotypes related to Chronic Neutrophilic Leukemia according to GeneCards Suite gene sharing:

25 (show all 24)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.78 IFNA2 IFNA1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-107 9.78 CSF3R
3 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.78 IFNA1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.78 CSF3R
5 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.78 IFNA2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-130 9.78 KMT2A
7 Increased shRNA abundance (Z-score > 2) GR00366-A-136 9.78 CSF3R
8 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.78 CSF3R
9 Increased shRNA abundance (Z-score > 2) GR00366-A-164 9.78 CSF3R
10 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.78 IFNA1 IFNA2 KMT2A CSF3R
11 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.78 IFNA2 IFNA1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-197 9.78 CSF3R
13 Increased shRNA abundance (Z-score > 2) GR00366-A-208 9.78 KMT2A
14 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.78 IFNA1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.78 IFNA2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.78 IFNA2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.78 IFNA1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.78 CSF3R
19 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.78 IFNA1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-78 9.78 IFNA1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.78 IFNA1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-8 9.78 IFNA1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-88 9.78 IFNA1 KMT2A
24 Decreased viability after Chlamydia trachomatis serovar L2 infection and TNF-alpha/CHX stimulation GR00206-A 8.96 BIRC3 XIAP

MGI Mouse Phenotypes related to Chronic Neutrophilic Leukemia:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.97 ASXL1 BIRC3 CALR CAPNS1 CD34 CSF3R
2 hematopoietic system MP:0005397 9.96 AFF1 ASXL1 BIRC3 CAPNS1 CD34 CSF3
3 immune system MP:0005387 9.81 CSF3 CSF3R KMT2A SRSF2 XIAP AFF1
4 mortality/aging MP:0010768 9.65 AFF1 ASXL1 BIRC3 CALR CAPNS1 CSF3R
5 muscle MP:0005369 9.1 XIAP BIRC3 CALR CAPNS1 KMT2A SRSF2

Drugs & Therapeutics for Chronic Neutrophilic Leukemia

Drugs for Chronic Neutrophilic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 230)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mycophenolic acid Approved Phase 3,Phase 1,Phase 2 24280-93-1 446541
2
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 1,Phase 2 128794-94-5 5281078
3
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
4
Morphine Approved, Investigational Phase 3 57-27-2 5288826
5
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
6
Ephedrine Approved Phase 3 299-42-3 9294
7
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
8
Pseudoephedrine Approved Phase 3 90-82-4 7028
9
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
10
Dextromethorphan Approved Phase 3 125-71-3 5362449 5360696
11
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
12
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
13
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
14
Moxifloxacin Approved, Investigational Phase 3 151096-09-2, 354812-41-2 152946
15
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
16
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
17 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
18 Analgesics Phase 3
19 Central Nervous System Depressants Phase 3,Phase 2,Phase 1
20 Neurotransmitter Agents Phase 3,Phase 2
21 Anesthetics Phase 3
22 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1
23 Anesthetics, Dissociative Phase 3
24 Dermatologic Agents Phase 3,Phase 2,Phase 1
25 Anesthetics, General Phase 3
26 Anesthetics, Intravenous Phase 3
27 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
28 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
29 Anti-Infective Agents Phase 3,Phase 2,Phase 1
30 Excitatory Amino Acid Antagonists Phase 3
31 Excitatory Amino Acids Phase 3
32 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
33 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
34 Antirheumatic Agents Phase 3,Phase 2,Phase 1
35 Calcineurin Inhibitors Phase 3,Phase 2,Phase 1
36 Antitubercular Agents Phase 3,Phase 1,Phase 2
37 Acyclovir Phase 3
38 valacyclovir Phase 3
39 Respiratory System Agents Phase 3,Phase 2
40 Adjuvants, Anesthesia Phase 3
41 Chlorpheniramine, phenylpropanolamine drug combination Phase 3
42 Narcotics Phase 3
43 Nasal Decongestants Phase 3
44 Tetrahydrozoline Phase 3,Phase 1,Phase 2
45 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
46 Cyclosporins Phase 3,Phase 1,Phase 2
47 Analgesics, Opioid Phase 3
48 Vasoconstrictor Agents Phase 3
49 Ophthalmic Solutions Phase 3,Phase 1,Phase 2
50 Pharmaceutical Solutions Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 112)

# Name Status NCT ID Phase Drugs
1 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
2 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
3 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
4 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
5 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
6 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
7 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
8 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
9 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
10 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
11 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
12 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
13 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
14 Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD) Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
15 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant Completed NCT00795769 Phase 2 ondansetron
16 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
17 Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer Completed NCT00823524 Phase 1, Phase 2
18 Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer Completed NCT00806767 Phase 2 busulfan;fludarabine phosphate
19 Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer Completed NCT00787761 Phase 2 busulfan;cyclophosphamide;fludarabine phosphate;methotrexate;tacrolimus
20 Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant Completed NCT00691015 Phase 2 busulfan;carmustine;cyclophosphamide;cytarabine;etoposide;fludarabine phosphate;melphalan;anti-thymocyte globulin IV
21 Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen Completed NCT00448357 Phase 1, Phase 2 busulfan;fludarabine phosphate;tacrolimus;methotrexate
22 Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant Completed NCT00410657 Phase 2 methylprednisolone;prednisone
23 Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant Completed NCT00357084 Phase 2 methotrexate;methylprednisolone;prednisone
24 Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer Completed NCT00346359 Phase 2 busulfan;fludarabine phosphate;methotrexate;tacrolimus
25 Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00245037 Phase 1, Phase 2 busulfan;cyclosporine;fludarabine phosphate;mycophenolate mofetil;Granulocyte colony-stimulating factor (G-CSF);Phenytoin;Methotrexate
26 Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant Completed NCT00110045 Phase 2 caspofungin acetate
27 Campath-1H + FK506 and Methylprednisolone for GVHD Completed NCT00109993 Phase 2 methylprednisolone;tacrolimus
28 Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00096096 Phase 2 mycophenolate mofetil;tacrolimus
29 Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00089037 Phase 1, Phase 2 methotrexate;sirolimus;tacrolimus
30 Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder Completed NCT00054340 Phase 1, Phase 2 busulfan;cyclophosphamide;cyclosporine;methotrexate
31 Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative Disorder Completed NCT00049634 Phase 1, Phase 2 busulfan;cyclophosphamide;cyclosporine;methotrexate
32 Non-Ablative Allo HSCT For Hematologic Malignancies or SAA Completed NCT00006379 Phase 2 cyclophosphamide;fludarabine phosphate
33 Bone Marrow Transplant in Treating Patients With Hematologic Cancers Completed NCT00005797 Phase 2 busulfan;Cyclophosphamide;VP-16
34 Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders Completed NCT00005622 Phase 2 cyclophosphamide
35 Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia Recruiting NCT02092324 Phase 2 Ruxolitinib Phosphate
36 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Recruiting NCT01384513 Phase 2 Fludarabine;Busulfan;Cyclophosphamide (CY);Tacrolimus;Mycophenolate mofetil
37 Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders Active, not recruiting NCT00544115 Phase 2 busulfan;cyclophosphamide;cyclosporine;etoposide;fludarabine phosphate;melphalan;methotrexate;mycophenolate mofetil;sirolimus;tacrolimus
38 Combination Chemotherapy, Tacrolimus, and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant For Hematologic Cancer Active, not recruiting NCT00134017 Phase 2 busulfan;cyclophosphamide;mycophenolate mofetil;tacrolimus
39 Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload Terminated NCT01159067 Phase 2 deferasirox
40 Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation Terminated NCT01116232 Phase 2 sirolimus;tacrolimus
41 Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease Terminated NCT00719849 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
42 Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant Terminated NCT00617929 Phase 2 clofarabine
43 Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer Terminated NCT00295880 Phase 1, Phase 2
44 Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer Terminated NCT00281879 Phase 2 busulfan;carmustine;cyclophosphamide;cyclosporine;cytarabine;etoposide;fludarabine phosphate;melphalan;methotrexate;methylprednisolone;mycophenolate mofetil;tacrolimus
45 Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies Withdrawn NCT01101412 Phase 1, Phase 2 Edetate Calcium Disodium;Ethanol;Trimethoprim-sulfamethoxazole
46 Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer Withdrawn NCT00816413 Phase 1, Phase 2 cyclosporine;mycophenolate mofetil;pentostatin
47 Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Withdrawn NCT00301912 Phase 2 busulfan;fludarabine phosphate;methotrexate;tacrolimus
48 Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections Unknown status NCT00769613 Phase 1
49 Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia Completed NCT01484015 Phase 1 cefepime hydrochloride
50 MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Completed NCT01231919 Phase 1 Akt inhibitor MK2206

Search NIH Clinical Center for Chronic Neutrophilic Leukemia

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Genetic Tests for Chronic Neutrophilic Leukemia

Anatomical Context for Chronic Neutrophilic Leukemia

MalaCards organs/tissues related to Chronic Neutrophilic Leukemia:

38
Neutrophil, Bone, Bone Marrow, Myeloid, Liver, Eye, Kidney

Publications for Chronic Neutrophilic Leukemia

Articles related to Chronic Neutrophilic Leukemia:

(show top 50) (show all 130)
# Title Authors Year
1
Chronic neutrophilic leukemia: new science and new diagnostic criteria. ( 29440636 )
2018
2
CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival. ( 29449543 )
2018
3
Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia. ( 28302714 )
2017
4
Targeted next-generation sequencing identifies clinically relevant mutations in patients with chronic neutrophilic leukemia at diagnosis and blast crisis. ( 28762112 )
2017
5
Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. ( 28983816 )
2017
6
Clinical significance of CSF3R, SRSF2 and SETBP1 mutations in chronic neutrophilic leukemia and chronic myelomonocytic leukemia. ( 28209919 )
2017
7
Granulocyte colony-stimulating factor receptor signaling in severe congenital neutropenia, chronic neutrophilic leukemia, and related malignancies. ( 27789332 )
2017
8
Changes in allele frequencies of CSF3R and SETBP1 mutations and evidence of clonal evolution in a chronic neutrophilic leukemia patient treated with ruxolitinib. ( 28209656 )
2017
9
Prognostic significance of SETBP1 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia, and chronic neutrophilic leukemia: A meta-analysis. ( 28158286 )
2017
10
Chronic neutrophilic leukemia 2016: Update on diagnosis, molecular genetics, prognosis, and management. ( 26700908 )
2016
11
Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia. ( 27068405 )
2016
12
Chronic neutrophilic leukemia in a child with a CSF3R T618I germline mutation. ( 27581359 )
2016
13
Dao K-HT, Tyner JW. What's different about atypical CML and chronic neutrophilic leukemia? Hematology Am Soc Hematol Educ Program. 2015;2015:264-271. ( 27913552 )
2016
14
Genomics of chronic neutrophilic leukemia. ( 28028025 )
2016
15
A CSF3R T618I Mutation in a Patient with Chronic Neutrophilic Leukemia and Severe Bleeding Complications. ( 26875968 )
2016
16
Splenic rupture in primary amyloidosis with chronic neutrophilic leukemia. ( 25830123 )
2015
17
What's different about atypical CML and chronic neutrophilic leukemia? ( 26637732 )
2015
18
ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia. ( 25850813 )
2015
19
Sweet's syndrome associated with chronic neutrophilic leukemia. ( 25751350 )
2015
20
A case of chronic neutrophilic leukemia successfully treated with pegylated interferon alpha-2a. ( 25983565 )
2015
21
Neutrophilic progression in a case of polycytemia vera mimicking chronic neutrophilic leukemia: Clinical and molecular characterization. ( 25480691 )
2015
22
Chronic neutrophilic leukemia: a clinical perspective. ( 26366092 )
2015
23
T618I-Mutated Colony Stimulating Factor 3 Receptor in Chronic Neutrophilic Leukemia and Chronic Myelomonocytic Leukemia Patients who Underwent Allogeneic Stem Cell Transplantation. ( 25932451 )
2015
24
Chronic neutrophilic leukemia: novel mutations and their impact on clinical practice. ( 25575036 )
2015
25
Concurrent chronic neutrophilic leukemia blast crisis and multiple myeloma: A case report and literature review. ( 26137042 )
2015
26
Chronic neutrophilic leukemia with overexpression of EVI-1, and concurrent CSF3R and SETBP1 mutations: A case report. ( 26622734 )
2015
27
Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia. ( 25239264 )
2014
28
CALR mutation studies in chronic neutrophilic leukemia. ( 24421250 )
2014
29
Treatment of coexisting chronic neutrophilic leukemia and light chain multiple myeloma with hydroxyurea, bortezomib, and dexamethasone. ( 25143840 )
2014
30
Chronic neutrophilic leukemia with plasma cell dyscrasia: friends or relatives? ( 23656197 )
2014
31
Chronic neutrophilic leukemia with concurrent CSF3R and SETBP1 mutations: single colony clonality studies, in vitro sensitivity to JAK inhibitors and lack of treatment response to ruxolitinib. ( 24445868 )
2014
32
Current strategies in the diagnosis and management of chronic neutrophilic leukemia. ( 25533830 )
2014
33
Chronic neutrophilic leukemia: a rare case report. ( 25332542 )
2014
34
Chronic neutrophilic leukemia 2014: Update on diagnosis, molecular genetics, and management. ( 24845374 )
2014
35
Nephrotic syndrome related to chronic neutrophilic leukemia. ( 25366011 )
2014
36
CSF3R, SETBP1 and CALR mutations in chronic neutrophilic leukemia. ( 25316523 )
2014
37
Molecular genetics of chronic neutrophilic leukemia, chronic myelomonocytic leukemia and atypical chronic myeloid leukemia. ( 25498990 )
2014
38
Chronic Neutrophilic Leukemia with V617F JAK2 Mutation. ( 24839370 )
2014
39
Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. ( 23656643 )
2013
40
Deletion of chromosome 17 as a novel cytogenetic finding in chronic neutrophilic leukemia: A case report. ( 23761837 )
2013
41
Presence of the JAK2 V617F mutation in a patient with chronic neutrophilic leukemia and effective response to interferon I+-2b. ( 23391844 )
2013
42
CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. ( 23604229 )
2013
43
Plasma cell neoplasm associated chronic neutrophilic leukemia with membrane proximal and truncating CSF3R mutations. ( 24033109 )
2013
44
Pregnancy in a woman with chronic neutrophilic leukemia. ( 23344408 )
2013
45
The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment. ( 23896413 )
2013
46
Severe congenital neutropenia and chronic neutrophilic leukemia: an intriguing molecular connection unveiled by oncogenic mutations in CSF3R. ( 24091926 )
2013
47
CSF3R is mutated in chronic neutrophilic leukemia and atypical CML. ( 23847367 )
2013
48
Imatinib therapy in a patient with suspected chronic neutrophilic leukemia and FIP1L1-PDGFRA rearrangement. ( 24203930 )
2013
49
CSF3R T618I co-occurs with mutations of splicing and epigenetic genes and with a new PIM3 truncated fusion gene in chronic neutrophilic leukemia. ( 24212483 )
2013
50
Rituximab for managing acquired hemophilia A in a case of chronic neutrophilic leukemia with the JAK2 kinase V617F mutation. ( 23248577 )
2012

Variations for Chronic Neutrophilic Leukemia

Expression for Chronic Neutrophilic Leukemia

Search GEO for disease gene expression data for Chronic Neutrophilic Leukemia.

Pathways for Chronic Neutrophilic Leukemia

GO Terms for Chronic Neutrophilic Leukemia

Biological processes related to Chronic Neutrophilic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 defense response GO:0006952 9.61 CSF3R IFNA1 IFNA2
2 regulation of type I interferon-mediated signaling pathway GO:0060338 9.46 IFNA1 IFNA2
3 T cell activation involved in immune response GO:0002286 9.4 IFNA1 IFNA2
4 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.37 IFNA1 IFNA2
5 natural killer cell activation involved in immune response GO:0002323 9.32 IFNA1 IFNA2
6 regulation of innate immune response GO:0045088 9.26 BIRC3 XIAP
7 cytokine-mediated signaling pathway GO:0019221 9.26 CSF3 CSF3R IFNA1 IFNA2
8 inhibition of cysteine-type endopeptidase activity involved in apoptotic process GO:1990001 9.16 BIRC3 XIAP
9 regulation of nucleotide-binding oligomerization domain containing signaling pathway GO:0070424 8.62 BIRC3 XIAP

Molecular functions related to Chronic Neutrophilic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine receptor binding GO:0005126 9.16 IFNA1 IFNA2
2 cysteine-type endopeptidase inhibitor activity involved in apoptotic process GO:0043027 8.96 BIRC3 XIAP
3 type I interferon receptor binding GO:0005132 8.62 IFNA1 IFNA2

Sources for Chronic Neutrophilic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....